Database Member Home
RAS Member Home
Key opinion leaders (KOL) play a significant role in a biopharmaceutical product’s development by providing clinical and scientific expertise during initial phase, influencing peers and serving as advocates and spokespersons at product launch. However, increasing regulatory restrictions have forced biopharmaceutical companies to reassess their approach to KOL management.
This video provides guidelines for effective KOL development and engagement to promote long term viability. It discusses the strategic approaches to thought leader management to be adopted by an organization as it evolves, KOL management responsibility in the organization and interpreting the impact of legislative changes on business operations.
Insights from this video will help Medical Affairs professionals in comparing their approach to Key Opinion Leader management against industry standards and identify scope for improvement.
A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95)
Read More »
Best Practices’ Market Research series highlights best practices in market research... (ID SMS-169)
Best Practices’ Pharma Thought Leadership series examines thought leadership in the context of patient advocacy while creating effective relationships and global product launches... (ID SMS-156)
The objective of this benchmarking study is to help biopharma leaders develop competitive launch and pre-launch activity budgets to ensure successful U... (ID PSM-326)
Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID PSM-229)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264)